Evaluation of growth hormone (GH) action in mice: Discovery of GH receptor antagonists and clinical indications

Research output: Contribution to journal › Review › Research › peer-review

Standard

Evaluation of growth hormone (GH) action in mice : Discovery of GH receptor antagonists and clinical indications. / Kopchick, John J.; List, Edward O.; Kelder, Bruce; Gosney, Elahu S.; Berryman, Darlene E.

In: Molecular and Cellular Endocrinology, Vol. 386, No. 1-2, 05.04.2014, p. 34-45.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Kopchick, JJ, List, EO, Kelder, B, Gosney, ES & Berryman, DE 2014, 'Evaluation of growth hormone (GH) action in mice: Discovery of GH receptor antagonists and clinical indications', Molecular and Cellular Endocrinology, vol. 386, no. 1-2, pp. 34-45. https://doi.org/10.1016/j.mce.2013.09.004

APA

Kopchick, J. J., List, E. O., Kelder, B., Gosney, E. S., & Berryman, D. E. (2014). Evaluation of growth hormone (GH) action in mice: Discovery of GH receptor antagonists and clinical indications. Molecular and Cellular Endocrinology, 386(1-2), 34-45. https://doi.org/10.1016/j.mce.2013.09.004

Vancouver

Kopchick JJ, List EO, Kelder B, Gosney ES, Berryman DE. Evaluation of growth hormone (GH) action in mice: Discovery of GH receptor antagonists and clinical indications. Molecular and Cellular Endocrinology. 2014 Apr 5;386(1-2):34-45. https://doi.org/10.1016/j.mce.2013.09.004

Author

Kopchick, John J. ; List, Edward O. ; Kelder, Bruce ; Gosney, Elahu S. ; Berryman, Darlene E. / Evaluation of growth hormone (GH) action in mice : Discovery of GH receptor antagonists and clinical indications. In: Molecular and Cellular Endocrinology. 2014 ; Vol. 386, No. 1-2. pp. 34-45.

Bibtex

@article{e5c4a71fff764477b01ab2995509c2f3,
title = "Evaluation of growth hormone (GH) action in mice: Discovery of GH receptor antagonists and clinical indications",
abstract = "The discovery of a growth hormone receptor antagonist (GHA) was initially established via expression of mutated GH genes in transgenic mice. Following this discovery, development of the compound resulted in a drug termed pegvisomant, which has been approved for use in patients with acromegaly. Pegvisomant treatment in a dose dependent manner results in normalization of IGF-1 levels in most patients. Thus, it is a very efficacious and safe drug. Since the GH/IGF-1 axis has been implicated in the progression of several types of cancers, many have suggested the use of pegvisomant as an anti-cancer therapeutic. In this manuscript, we will review the use of mouse strains that possess elevated or depressed levels of GH action for unraveling many of GH actions. Additionally, we will describe experiments in which the GHA was discovered, review results of pegvisomant's preclinical and clinical trials, and provide data suggesting pegvisomant's therapeutic value in selected types of cancer.",
keywords = "FaGHRKO, GHA, GHR-/- mice, Growth hormone receptor antagonist (GHA), Pegvisomont, Somavert",
author = "Kopchick, {John J.} and List, {Edward O.} and Bruce Kelder and Gosney, {Elahu S.} and Berryman, {Darlene E.}",
year = "2014",
month = apr,
day = "5",
doi = "10.1016/j.mce.2013.09.004",
language = "English",
volume = "386",
pages = "34--45",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

RIS

TY - JOUR

T1 - Evaluation of growth hormone (GH) action in mice

T2 - Discovery of GH receptor antagonists and clinical indications

AU - Kopchick, John J.

AU - List, Edward O.

AU - Kelder, Bruce

AU - Gosney, Elahu S.

AU - Berryman, Darlene E.

PY - 2014/4/5

Y1 - 2014/4/5

N2 - The discovery of a growth hormone receptor antagonist (GHA) was initially established via expression of mutated GH genes in transgenic mice. Following this discovery, development of the compound resulted in a drug termed pegvisomant, which has been approved for use in patients with acromegaly. Pegvisomant treatment in a dose dependent manner results in normalization of IGF-1 levels in most patients. Thus, it is a very efficacious and safe drug. Since the GH/IGF-1 axis has been implicated in the progression of several types of cancers, many have suggested the use of pegvisomant as an anti-cancer therapeutic. In this manuscript, we will review the use of mouse strains that possess elevated or depressed levels of GH action for unraveling many of GH actions. Additionally, we will describe experiments in which the GHA was discovered, review results of pegvisomant's preclinical and clinical trials, and provide data suggesting pegvisomant's therapeutic value in selected types of cancer.

AB - The discovery of a growth hormone receptor antagonist (GHA) was initially established via expression of mutated GH genes in transgenic mice. Following this discovery, development of the compound resulted in a drug termed pegvisomant, which has been approved for use in patients with acromegaly. Pegvisomant treatment in a dose dependent manner results in normalization of IGF-1 levels in most patients. Thus, it is a very efficacious and safe drug. Since the GH/IGF-1 axis has been implicated in the progression of several types of cancers, many have suggested the use of pegvisomant as an anti-cancer therapeutic. In this manuscript, we will review the use of mouse strains that possess elevated or depressed levels of GH action for unraveling many of GH actions. Additionally, we will describe experiments in which the GHA was discovered, review results of pegvisomant's preclinical and clinical trials, and provide data suggesting pegvisomant's therapeutic value in selected types of cancer.

KW - FaGHRKO

KW - GHA

KW - GHR-/- mice

KW - Growth hormone receptor antagonist (GHA)

KW - Pegvisomont

KW - Somavert

UR - http://www.scopus.com/inward/record.url?scp=84896726383&partnerID=8YFLogxK

U2 - 10.1016/j.mce.2013.09.004

DO - 10.1016/j.mce.2013.09.004

M3 - Review

C2 - 24035867

AN - SCOPUS:84896726383

VL - 386

SP - 34

EP - 45

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

IS - 1-2

ER -

ID: 202371219